News

The performance and operation of the Latvian Medicines Verification System (LZVS) in the first quarter of 2024 have been stable. In the first quarter of 2024, a total of 29 million transactions were carried out in the LZVS, which is a 6% increase compared to the corresponding period in 2023.

While setting up the Lithuanian Medicines Verification Organization (NVVO) came with its challenges in the beginning, ever since its founding back in 2017 we have not swayed from our goal: to ensure the safety of medicines for patients.

During the members' meeting of the Latvian Medicines Verification Organisation (LZVO) on April 10, the association's 2023 annual report was approved. The meeting also discussed current issues and future plans regarding the organization’s activities—such as financial management, financial risks, and their management principles, as well as the maintenance and development of the medicines verification system.

Latvijas Zāļu verifikācijas organizācija (LZVO) aicina visus LZVS gala lietotājus un IT piegādātājus pārliecināties, kāda interfeisa versija šobrīd tiek izmantota, un nepieciešamības gadījumā uzstādīt jauno versiju.

LZVO (Latvijas Zāļu verifikācijas organizācija) releases newsletter No. 8, where you can find the most important information about events in the world of pharmaceutical verification in 2024 as well on the previous five years. Also our neighbors in Estonia sharing their experience story.

The European Medicines Verification System, operating since 2019 in accordance with the EU Directive and Delegated Regulation, is a comprehensive, pan-European system covering all EU and EEA countries, connecting 2,800 pharmaceutical companies, 4,000 wholesalers, 110,000 pharmacies and 6,000 hospital pharmacies online, including all Latvian end users.